🚨 Everything is back in stock — all peptides available now 🚨

SS-31 (elamipretide)

APPROVED MEDICINE

Approved in the US in 2025 as Forzinity, for Barth syndrome only. Trials in other conditions largely failed.

At a glance. One of the few peptides that acts directly on mitochondrial structure, with a genuine approval for one rare disease.

Written and maintained by the AVERON Research Desk · Last reviewed September 2026

What it is

SS-31 is a small peptide of four amino acids, developed by Hazel Szeto and Peter Schiller. As a drug it is called elamipretide. It concentrates in the inner membrane of mitochondria, where it binds to cardiolipin, a fat molecule that holds the energy-producing machinery of the mitochondria in place.

By stabilising cardiolipin, SS-31 is proposed to help mitochondria produce energy more efficiently and to reduce damage caused when they malfunction.

What researchers study it for

Rare inherited mitochondrial diseases, particularly Barth syndrome and primary mitochondrial myopathy, as well as heart failure and age-related eye disease.

What the research shows

Barth syndrome. A rare genetic disease that affects cardiolipin directly and causes muscle weakness and heart problems. In the TAZPOWER trial and its extension, elamipretide was associated with improvements in muscle strength. On 19 September 2025, the US FDA granted it accelerated approval as Forzinity, to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. It was the first approved treatment for the disease. Under accelerated approval, further confirmatory evidence is required.

Primary mitochondrial myopathy. The phase 3 MMPOWER-3 trial, published by Amel Karaa and colleagues in Neurology in 2023, did not meet its primary goals: elamipretide did not improve walking distance or fatigue compared with placebo.

Other conditions. Trials in heart failure and age-related eye disease have also largely failed to show clear benefit.

What it does not do, and what is not known

  • Its approval covers Barth syndrome only. It is not approved for any other use.
  • It failed its largest trial, in primary mitochondrial myopathy, which is the condition closest to what most people hope it will do.
  • There is no evidence that it improves energy, fitness or ageing in healthy adults.
  • The accelerated approval depends on further confirmatory evidence.
  • Research-grade material is not Forzinity.

Adverse effects reported in research

Reactions at the injection site were by far the most common adverse effect across trials, including redness, itching and swelling. Headache and dizziness were also reported. It was generally well tolerated in the published trials.

Regulatory and anti-doping status

Regulatory: Approved by the US FDA in September 2025 as Forzinity, for Barth syndrome, under accelerated approval.

Anti-doping: As a substance with a current approval, it does not fall under WADA's category S0, and it is not named elsewhere on the Prohibited List. Athletes should confirm with their anti-doping organisation.

At AVERON

SS-31 is not yet in stock. When it arrives, it will be listed in the shop, and its independent lab report will be published on our verify page before it is sold.

Frequently asked questions

Yes, in the United States since September 2025, as Forzinity, for Barth syndrome only.

No. The phase 3 MMPOWER-3 trial did not meet its primary goals.

None. SS-31 is the research name and elamipretide is the drug name.

There is no evidence that it does.

Doses mentioned on this page are the arms of published studies or the terms of an approved product, given to describe the evidence. They are not guidance.

Sources

  1. U.S. Food and Drug Administration. Approval package for Forzinity (elamipretide), NDA 215244. FDA. Link
  2. Karaa A, Bertini E, Carelli V, et al.. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology, 2023;101(3):e238–e252. Link
  3. ClinicalTrials.gov. TAZPOWER, NCT03098797. ClinicalTrials.gov. Link

Related pages

...